COVID-19 in pediatric kidney transplantation: a follow-up report of the Improving Renal Outcomes Collaborative.
COVID-19
Improving Renal Outcomes Collaborative
Kidney transplant
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
08
02
2022
accepted:
30
03
2022
revised:
30
03
2022
pubmed:
11
5
2022
medline:
22
12
2022
entrez:
10
5
2022
Statut:
ppublish
Résumé
We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC). Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test. From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19. Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC).
METHODS
Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test.
RESULTS
From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19.
CONCLUSIONS
Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 35538239
doi: 10.1007/s00467-022-05570-w
pii: 10.1007/s00467-022-05570-w
pmc: PMC9090538
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-547Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK126807
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001426
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Goss MB, Galvan NTN, Ruan W, Munoz FM, Brewer ED, O’Mahony CA, Melicoff-Portillo E, Dreyer WJ, Miloh TA, Cigarroa FG, Ranch D, Yoeli D, Adams MA, Koohmaraie S, Harter DM, Rana A, Cotton RT, Carter B, Patel S, Moreno NF, Leung DH, Goss JA (2020) The pediatric solid organ transplant experience with COVID-19: an initial multi-center, multi-organ case series. Pediatr Transplant 25:e13868. https://doi.org/10.1111/petr.13868
doi: 10.1111/petr.13868
Marlais M, Wlodkowski T, Al-Akash S, Ananin P, Bandi VK, Baudouin V, Boyer O, Vasquez L, Govindan S, Hooman N, Ijaz I, Loza R, Melgosa M, Pande N, Pape L, Saha A, Samsonov D, Schreuder MF, Sharma J, Siddiqui S, Sinha R, Stewart H, Tasic V, Tonshoff B, Twombley K, Upadhyay K, Vivarelli M, Weaver DJ, Woroniecki R, Schaefer F, Tullus K (2020) COVID-19 in children treated with immunosuppressive medication for kidney diseases. Arch Dis Child 106:798–801. https://doi.org/10.1136/archdischild-2020-320616
doi: 10.1136/archdischild-2020-320616
Mastrangelo A, Morello W, Vidal E, Guzzo I, AnnicchiaricoPetruzzelli L, Benetti E, Materassi M, Giordano M, Pasini A, Corrado C, Puccio G, Chimenz R, Pecoraro C, Massella L, Peruzzi L, Montini G, COVID-19 Task Force of the Italian Society of Pediatric Nephrology (2021) Impact of COVID-19 pandemic in children with CKD or immunosuppression. Clin J Am Soc Nephrol 16:449–451
doi: 10.2215/CJN.13120820
Angeletti A, Trivelli A, Magnasco A, Drovandi S, Sanguineri F, Santaniello M, Ferrando G, Forno R, Cipresso G, Tripodi G, Riella LV, Cravedi P, Ghiggeri GM (2020) Risk of COVID-19 in young kidney transplant recipients. Results from a single-center observational study. Clin Transplant 34:e13889. https://doi.org/10.1111/ctr.13889
doi: 10.1111/ctr.13889
Varnell CD, Harshman L, Smith L, Liu C, Chen S, Al-Akash S, Barletta GM, Belsha C, Brakeman P, Chaudhuri A, Fadakar P, Garro R, Gluck C, Goebel J, Kershaw D, Matossian D, Nailescu C, Patel HP, Pruette C, Ranabothu S, Rodig N, Smith J, VanSickle J, Danziger-Isakov LA, Hooper DK, Seifert M (2021) COVID-19 in pediatric kidney transplantation: the Improving Renal Outcomes Collaborative. Am J Transplant 21:2740–2748
doi: 10.1111/ajt.16501
Hooper DK, Misurac J, Blydt-Hansen T, Chua AN (2020) Multicenter data to improve health for pediatric renal transplant recipients in North America: complementary approaches of NAPRTCS and IROC. Pediatr Transplant 25:e13891. https://doi.org/10.1111/petr.13891
doi: 10.1111/petr.13891
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381
doi: 10.1016/j.jbi.2008.08.010
Centers for Disease Control and Prevention (2022) CDC COVID-19 case line-level data. https://covid.cdc.gov/covid-data-tracker/#demographicsovertime . Accessed 28 February 2022
Badal S, Thapa Bajgain K, Badal S, Thapa R, Bajgain BB, Santana MJ (2021) Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: a systematic review and meta-analysis. J Clin Virol 135:104715
doi: 10.1016/j.jcv.2020.104715
Mehta NS, Mytton OT, Mullins EWS, Fowler TA, Falconer CL, Murphy OB, Langenberg C, Jayatunga WJP, Eddy DH, Nguyen-Van-Tam JS (2020) SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. Clin Infect Dis 71:2469–2479
doi: 10.1093/cid/ciaa556
Patel NA (2020) Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 41:102573. https://doi.org/10.1016/j.amjoto.2020.102573
doi: 10.1016/j.amjoto.2020.102573
Melgosa M, Madrid A, Alvarez O, Lumbreras J, Nieto F, Parada E, Perez-Beltran V, Spanish Pediatric Nephrology Association (2020) SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. Pediatr Nephrol 35:1521–1524
Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, Zhang J, Dong C, Na R, Zheng L, Li W, Liu Z, Ma J, Wang J, He S, Xu Y, Si P, Shen Y, Cai C (2021) A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). J Med Virol 93:1057–1069
doi: 10.1002/jmv.26398
Leeb RT, Price S, Sliwa S, Kimball A, Szucs L, Caruso E, Godfred-Cato S, Lozier M (2020) COVID-19 trends among school-aged children - United States, March 1–September 19, 2020. Morb Mortal Wkly Rep 69:1410–1415. https://doi.org/10.15585/mmwr.mm6939e2
doi: 10.15585/mmwr.mm6939e2
Canpolat N, Yildirim ZY, Yildiz N, Tasdemir M, Goknar N, Evrengul H, Gulmez R, Aksu B, Dursun H, Ozcelik G, Yavascan O, Cicek RY, Tulpar S, Hacihamdioglu DO, Nayir A, Alpay H (2022) COVID-19 in pediatric patients undergoing chronic dialysis and kidney transplantation. Eur J Pediatr 181:117–123
doi: 10.1007/s00431-021-04191-z
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M (2021) Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 385:585–594
doi: 10.1056/NEJMoa2108891
US Food and Drug Administration (2021) FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age . Accessed 20 December 2021